Effectiveness of Atorvastatin in the Treatment of Asymptomatic Heart Failure After Myocardial Infarction: A Clinical Stu
- PDF / 530,375 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 113 Downloads / 193 Views
ORIGINAL RESEARCH
Effectiveness of Atorvastatin in the Treatment of Asymptomatic Heart Failure After Myocardial Infarction: A Clinical Study Dong Wang . Long Bai . Xiao-Ran Cui . Xiao-Hong Yang . Ji-Dong Zhang
Received: April 29, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: Silent heart failure after myocardial infarction has not been effectively treated. Atorvastatin has certain efficacy in the treatment of heart failure. Our clinical study aimed to investigate the effectiveness of atorvastatin in patients with asymptomatic heart failure after myocardial infarction. Methods: A total of 162 patients with asymptomatic heart failure after myocardial infarction in our hospital from August 2018 to August 2019 were randomly divided into the observation group (81 cases were treated with atorvastatin on the basis of routine therapy) and the control group (81 cases were treated with routine symptomatic treatment). The clinical curative effect, the level of related inflammatory cytokines, cardiac function index, and vascular endothelial function were compared between the two groups. Results: Before intervention, there was no significant difference in tumor necrosis factor (TNFa), high-sensitivity C-reactive protein (hsDigital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12619592. D. Wang L. Bai X.-R. Cui X.-H. Yang (&) J.-D. Zhang The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China e-mail: [email protected]
CRP), interleukin-6 (IL-6), plasma N-terminal B-type natriuretic peptide (NT-ProBNP), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular posterior wall thickness (LVPWT), asymmetric dimethyarginine (ADMA), activity of nitric oxide synthase (NOS), nitric oxide (NO) and flow-mediated dilation (FMD) between the two groups. After intervention, TNFa, hs-CRP, IL-6, NT-ProBNP, LVEF, LVEDD, LVESD, LVPWT, ADMA, NOS, NO, and FMD were improved in both groups. The clinical curative effect, TNFa, hs-CRP, IL-6, NT-ProBNP, LVEF, LVEDD, LVESD, LVPWT, ADMA, NOS, NO, and FMD in the observation group showed significantly greater results than those in the control group (P \ 0.05). Conclusion: Atorvastatin exerted a great effect in treating asymptomatic heart failure after myocardial infarction, which can evidently reduce the level of related inflammatory cytokines, improve cardiac function, and regulate vascular endothelial function. Hence, atorvastatin is considered a valid and alternative approach in clinical practice. Keywords: Asymptomatic heart failure after myocardial infarction; Atorvastatin; Cardiac function; Clinical effect
Adv Ther
Key Summary Points Why carry out this study? Some patients with myocardial infarction develop asymptomatic heart failure, but if symptoms of heart failure emerge, patients could suffer from worse conditions and even death. At pr
Data Loading...
